Thank you very much, and welcome everybody to Implantica's Q3 presentation. Implantica, as you know, is all about bringing advanced technology into the body, and we are specifically focusing a lot on eHealth implants. I will try to explain a bit about this during the presentation here. Myself, as you know, I'm a surgeon, invested lots of funds in this company and strongly believe Implantica will be a really interesting prospect going forward. A little overview of the company. As said, we are focusing a lot on eHealth and eHealth will revolutionize healthcare. It will be a total change. You know, if you look at the advancements that have been done outside the body, and you see how miniaturization has gone through everything with mobile phones, internet, interconnection, it's a dramatic change. I mean, if you take 20 years back and you take a computer, you get the same thing, a small little chip of 1 cm today. It's just an incredible development, and this has not yet reached the body, and that's what we are doing here. We will be able to improve lots of different treatments and even treat new things because it was not possible before in a good way. This will also save lots of cost for society because the good thing is here that you can do treatment on distance, and that means that patients, they don't need to come to the hospital as often as before. They don't need to stay at the hospital as before, and this will be a clearly substantial advantage for society. It also will be something that will bring treatment closer to the patient. Patients will be more involved, they will feel more in charge, and it will overall increase patients' quality of life. This revolution will happen independent of Implantica or not, and we want to be a big part of that journey. We have developed two platform technologies that is the fundament for be able to doing this nice e-health products. First of all, you realize that you run out of battery very quickly. As soon as you should do something that is more advanced and have more features, more functions, you know, your battery runs out immediately. It's impossible to do anything without a wireless energy supply. You need to be able to supply energy through intact skin, recharge your battery, or run your implant directly, and that's why we have developed this wireless energizing platform. Furthermore, you need now to control what you are doing inside the body. All is about these advanced features, and therefore you of course need to measure that inside the body. You need to measure, you know, the treatment, how is the treatment going, lots of patient parameters. You need to have control of your implant parameters. All this needs to be sent to the caregiver, and the caregiver could, on distance, log in. He could see his patient with a bank type of login, and he can then judge how the treatment is going and should be able to change the treatment on distance. That's the key here. Treatment should be changed on distance. Implantica is in the absolutely forefront of this new technology. Not only that, when you build all this setup with this eHealth functionality and these products and so on, you can do that in a modular way. You can build modules. You have, you know, your functional part of the implant in motor pumps. That's one module. You have the wireless energy receiver is another module. You have the treatment unit, another module, and so on. You can, in a very smart way, build systems that could be combined in different combinations for new implants. Because the good thing here, you know, is that Implantica has a pipeline of many, many products because we went through the whole body and looked for what could you do with these platform technologies. We have gone through treatment field after treatment field. We have looked at existing treatments, existing patents. We have read more than 15,000 patents, and we have created new patents for the new technology. We made more than 300 individual inventions, and those has been very, very heavily penetrated by 70 people for 3 years with market analysis, product analysis, production analysis, prototyping, and we have then selected 40, what we believe, strong, viable implant products. That's why it's so attractive to build this in modules, so you can combine different modules and more quickly, more efficiently get new products on the market when you finally get up and running. Our first product, which people are quite interesting because it's already on the market, is a treatment for acid reflux. That's not an e-health product because this was a very simple, genius product that was able to put on the market more quickly, and this is for treating acid reflux. People who have stomach acid coming up in their esophagus causing pain, you know, it gets red, irritated, mini ulcers. The problem with this disease is not only that people take a drug that is quite dangerous to take because you need to take it for your life, and it has lots of complications. The most serious here is that 48,000 people die from esophageal adenocarcinoma in Europe and United States alone. That's 48,000 deaths. This is a really, really dangerous disease here because nearly all of those are caused by acid reflux. That's because the acid comes up in your lower esophagus, and it terrorizing tissue, and it does that over and over and over again, and therefore you get the precancerous changes, and finally you get your cancer and die. This is a totally unbearable situation for the patients, and something need to be done. The drugs don't stop reflux. They only reduce the acidity, so you have less pain, but it doesn't stop the cancer risk. Karolinska has made a big literature review. It's zero change of cancer risk. That you can also see when you see how this cancer has developed, and you see that in men, it has been 10-folded this cancer in 40 years. PPI, the drugs here, were introduced 1988. This should, of course, reduce the cancer risk, not give a 10-fold increase if it has any effect on this risk, which it doesn't have. We have then been able to find out, you know, the cause of acid reflux and why you get acid reflux, and we can then treat acid reflux in a very attractive way. Some surgical methods has been used also in the past, and they have all been focusing how do I close my ring muscle, my sphincter that should close from stomach and up the esophagus. They put pressure on the outside, either by taking the top part of the stomach and wrap it around, called fundoplication, or Johnson & Johnson has a new device called LINX system. This is a magnetic band that is then, you know, trying to support the closing here. The problem, however, is that this is people's food passageway, and of course, if you try to close that from the outside, you get swallowing problems. You can get nothing up. You could not vomit anymore. You could not belch anymore. You could not get any kind of gas up anymore, so you get so-called gas bloating, swollen the stomach. I worked 10 years with these patients at Karolinska, and no one is really happy with this type of surgery. How does it now work to treat the cause instead of acid reflux, instead not affecting the food passageway at all? The answer is the following. You have the chest and you have the abdomen. You have a big muscle called diaphragm that is dividing the chest from abdomen. It's moving up and down when you are breathing, and therefore you get pressure variations in the chest. With the breathing, the pressure is coming and going, coming and going, and that's then leaking out through the opening you have here because esophagus, of course, need to pass this muscle. Otherwise, you know, it can't come up to the, to the mouth, so to say. Here is leaking out pressure variations through this opening. These pressure variations, they affect this closing muscle here. If this closing muscle, this sphincter here, called lower esophageal sphincter, if this comes too close up to the diaphragm, then you get acid reflux. If it even enter the chest, then you call it a hernia, and you for sure has acid reflux. Our device is just like a little volume filler placed on the outside of the stomach wall, and it just acts like a mechanical stop. You always, independent of the movement of the diaphragm, you get this really large distance between the diaphragm and the closing muscle. When you see the results and compare with Johnson & Johnson's main product, our main device competitor here, this is their FDA trial. It's, you know, research could differ in quality, and with the FDA trial, you know that you really get the right quality. You can see that the results here, they're basically like night and day. It's a completely different league of treatment results and risk. If we then look a bit what has happened during this quarter here, we have something that we are really proud of, and that's that FDA, they have indicated that they would be willing to accept a PMA application for approval in the U.S. based on existing European data. We will put together existing data like we have today. It's 4.5 years, and we are doing that right now. That's an incredible achievement, I can tell you. I think we are the second case in the world so far where they accept European data for a PMA like this. We should be really, really proud of this, and that's of course related to that we have these fantastic results. We are also of course focusing on our other markets, and as you know, Japan is also a large market, and that's our next largest target now to really also get something similar done in Japan. This is to build, you know, so we finally could get some good business, which has been, as you know, a bit affected by this pandemic we have and have had in this world. What happened more during this quarter, I contributed EUR 170 million of assets in terms of a company called MedicalTree, 51%, which has some really interesting products that has enormous synergies with Implantica's product. We had got some question regarding the remaining 49% of each company, and I just wanted to confirm that this, what will happen with that, is totally dependent on the other shareholders' decision. I will not involve in any decision about anything of ownership of MedicalTree. Like the other transactions we made, you know, all was totally. I can't even say it in English. It was all shareholders agreed to this decision, and nothing here will be happening without that. It has some really extraordinary synergies, and one of them is drug delivery. You may be aware of that cancer is a real threat in this world. It's 19.3 million cancer cases every year, and the majority of those, they get chemotherapy. They get cytostatic treatment. This is a market that is forecasted to become EUR 74 billion by 2027. These drugs, they need to be given directly into a blood vessel. The problem you have with that when you should give long-term therapy, you know, chemotherapy, that you take for three weeks, and you wait a few weeks, then you take another three weeks, and wait, and another three weeks. Often they stay at hospital, maybe the whole first treatment. They come and go every day, follow up to the hospital. It's a nightmare for the patient, and it costs lots of money for society. If you can do treatment on distance, if you control the treatment on distance, you will have a great advantage and a relief for these patients. We have a new system to avoid these blood clots you get by putting, you know, catheter in, so your bloodstream, you get blood clots, and it doesn't work anymore. We have a system with a needle that injects inside the body, directly into the blood vessel, give the drug, and out again. It moves to next position, next position. Every time you get an injection, it's in a new position. You can continue more or less forever to give this treatment without affecting any blood clotting or any negative situation for the patients. They could come maybe, you know, once per month, once per week to refill the drug, but they don't need this continuously going to the hospital. That is something we really. It's lots of development done here. It's very far, this product, and we are really looking forward to really dig into this device. We as the team here in Implantica has also been focusing on reinforcing the team. In this respect, you should know that we do as we do with all our implants, with everything we do, we try to maximize the absolutely best. We have been searching all over the world to find the absolutely top, top people we can attract, because we are targeting to build a large company going forward, and that will be dependent totally on the key people that will drive this. It's not enough with one person to drive a company. You need a full team of really fully professional people, and that's what you see here, that we have been targeting everything from commercial, you know, with Chief Commercial Officer, VP Marketing, Chief Market Access, R&D. Everywhere, we have been trying the same principle, find the best people. I can show you here, for example, how it looks. Here you have new hires who is employed since August. You have, you know, VP Marketing, Chief Commercial Officer, VP Quality Regulatory, and so on and so on. Chief Market Access Officer. Here you can see the people who's starting on the December, January. We are really, you know, focusing to build a really excellent team because we as management strongly believe in Implantica. I can give you one example here of a person who is the Chief Market Access and Strategy Officer. This person is called Amit Kushwaha, and he is a real specialist in reimbursement, in health economics, you know, to get the payers to pay for the device. That's the key we have realized in this bureaucratic world. It's all about getting someone to pay for your device. That's sort of the key. We have been looking all over the world, and we dare to say that we believe we have the best people, the best person available all over the world for this target. It's a really experienced person in this area. What about the commercialization? As you know, we have a little bit of a pandemic which actually still affects the situation. As you know, in the U.K., they have a one-year waiting list now after the pandemic, and, you know, we have a fourth wave coming up. Many hospitals now in Germany, they say, "We don't do any more surgery this year," and so on and so on. You know, we are fighting a bit uphill, but this is just a hiccup for a company like Implantica. It doesn't really matter for those who is a little bit long term. We will regain this situation. There's no need to worry because of the pandemic. I'm sure this will be under control going forward. As an example, you know, we have four of the most prominent U.K. surgeons has been going through training now and are looking for patients to start to operate in U.K. After the Q3, we had another three centers here in Germany that we have also been able to train, you know. It's going on. That will be more and more surgeries, more and more hospitals, but it's a little bit delayed, as you know, the whole thing. Here you see a little bit of about the training centers we have. We have quite a few centers now who really is doing regularly. In Switzerland, for example, we have Inselspital in Bern, the largest university hospital in Switzerland. We have some, for example, Hirslanden, a private group hospital are starting to do Professor Sethi, for example, also in Bern. Other centers who has been developing really nice for us, for example, Friedrichshafen, they were planned during November to do 7 surgeries, but then suddenly they closed down, you know, and said, "Sorry, no more surgeries due to the pandemic." Which is, as you know, much worse in Germany than in Sweden. In Sweden, it's quite nice nowadays. Yeah, this is a little bit, we are employing new people now in both Spain and Italy to focus on these reimbursement countries here. It's under development. We have employed new person here in Sweden. We have one hospital starting up here now in Stockholm, and it's step by step going forward. All those things takes a little bit longer than planned in this situation. I think it's time for Andreas to speak a little bit about the finances. Excellent. Many thanks, Peter. I will briefly provide a Q3 financial snapshot. We should now be on slide 28. You might recognize this slide format from earlier periods. On the top graphs, we present Q3 numbers. On the bottom graphs, we show the nine-month numbers. I will here only walk through Q3. If you look at net sales, there we experience a year-on-year increase of 207% to EUR 83,000. As you're aware, we are currently only marketing our initial product, RefluxStop. Over Q3 and also in Q4, as Peter mentioned, we do continue to experience the impact of COVID-19 on elective surgeries. Turning to gross margin in the middle of the slide, we saw adjusted gross margin being flat year-on-year at 96%. The gross margin level that we currently experience and also expect to be experiencing for our lead product, RefluxStop, is fairly remarkable. Turning to EBIT operating loss, our quarterly loss decreased year-over-year from EUR 4.8 million to EUR 3.9 million. This development does not in an accurate way depict the underlying developments. As in Q3 2020, the comparable period, we booked EUR 3.5 million of IPO transaction cost through the P&L. If we adjust for these costs, we see that OpEx increased in a significant way compared to the period one year back. This is in line with our plan to build our commercial capabilities, including sales, market access, regulatory affairs, and further intensify our R&D activities, which we have been doing over the quarter, both in terms of the development of the eHealth platform and our pipeline products. Switching to slide 29. End of September, we held EUR 135.5 million of cash and short-term investments on the balance sheet and no interest-bearing debt on our books. With that, I would turn to slide 30, where we have an overview of shareholders. This list looks a bit different to the earlier periods as a consequence of the non-diluted merger between Implantica AG and Implantica MediSwiss, the former holding company, where Peter, as the founder and other pre-IPO investors, have their shareholdings. One can now see that, you know, the bulk of investors are Swedish and now also Swiss institutions. With that, I would hand it back to Peter. Yeah. I put a little bit summary of the key events during this quarter here. I think more or less we have discussed this already. I think we move on to questions. Thank you. If you do wish to ask a question, please press zero one on your telephone keypad. If you wish to withdraw your question, you may do so by pressing zero two to cancel. We will take a short break before questions are being registered. There are no questions at this moment. I hand back over to our speakers. Okay. No, but then we would like to thank everybody for listening, and we will do our best to continue an exciting journey. We wish everybody a good day.